Chemed Corporation
HealthcareNYSE:CHE · New York Stock Exchange
-$1.56 today
Vol 0.12M · Avg 0.25M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.5B of revenue converted into $259.8M of net income for the selected period. Gross margin is 30.3% and net margin is 10.2%, showing how much revenue survives after costs and taxes. EPS is $18.36, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B +4.1% | $2.4B +7.4% | $2.3B +6.1% | $2.1B -0.2% | $2.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.8B +12.3% | $1.6B +7.6% | $1.5B +7.0% | $1.4B +0.0% | $1.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $758.3M -11.2% | $854.3M +7.0% | $798.8M +4.4% | $765.1M -0.6% | $769.8M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 30.0% -5.2pp | 35.1% -0.1pp | 35.3% -0.6pp | 35.8% -0.1pp | 36.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $417.2M -1.7% | $424.4M +7.4% | $395.1M +10.1% | $358.7M -2.2% | $366.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $417.2M -14.5% | $487.9M +6.5% | $458.2M +8.7% | $421.6M -1.2% | $426.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $64.8M +2.8% | $63.0M +3.6% | $60.9M +2.9% | $59.2M +0.2% | $59.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | $422.4M -9.0% | $464.3M +12.1% | $414.3M +5.3% | $393.4M -4.3% | $411.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 16.7% -2.4pp | 19.1% +0.8pp | 18.3% -0.1pp | 18.4% -0.8pp | 19.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $338.2M -7.7% | $366.5M +7.6% | $340.6M -0.9% | $343.5M +0.1% | $343.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 13.4% -1.7pp | 15.1% +0.0pp | 15.0% -1.0pp | 16.1% +0.1pp | 16.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.7M -40.1% | $14.6M +133.0% | $6.3M +1666.2% | $355.0K -5.8% | $377.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.8M -1.7% | $1.8M -42.7% | $3.1M -32.2% | $4.6M +145.4% | $1.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $17.5M -46.8% | $33.0M +236.5% | $9.8M +170.9% | -$13.8M -289.9% | $7.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $355.8M -10.9% | $399.5M +14.0% | $350.4M +6.3% | $329.7M -5.9% | $350.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 14.1% -2.4pp | 16.4% +1.0pp | 15.5% +0.0pp | 15.4% -0.9pp | 16.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $90.5M -7.1% | $97.5M +25.2% | $77.9M -2.7% | $80.1M -2.1% | $81.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $265.2M -12.2% | $302.0M +10.8% | $272.5M +9.2% | $249.6M -7.0% | $268.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 10.5% -1.9pp | 12.4% +0.4pp | 12.0% +0.3pp | 11.7% -0.9pp | 12.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $18 -8.4% | $20 +11.0% | $18 +8.3% | $17 -2.5% | $17 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $18 -7.4% | $20 +10.9% | $18 +8.5% | $17 -1.9% | $17 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $14.4M -4.2% | $15.0M -0.2% | $15.1M +0.8% | $14.9M -4.7% | $15.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $14.4M -5.2% | $15.2M -0.1% | $15.2M +0.7% | $15.1M -5.3% | $15.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Bruker Corporation
NASDAQ:BRKR
$8.26B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Metsera, Inc.
MTSR
$7.43B
Teleflex Incorporated
NYSE:TFX
$5.78B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Option Care Health, Inc.
NASDAQ:OPCH
$3.26B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CHE generate?
Chemed Corporation (CHE) reported $2.53B of revenue in fiscal 2025.
Is CHE profitable?
Chemed Corporation (CHE) reported $265.24M of net income, with a net margin of 10.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.